Health care stocks advanced Thursday afternoon, with the NYSE Health Care Index rising 0.4% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%.
The iShares Biotechnology ETF (IBB) shed 0.5%.
In corporate news, UnitedHealth Group's (UNH) Q4 results increased on an annual basis, but revenue fell short of market expectations, while the health insurer kept its full-year outlook unchanged on Thursday. Its shares dropped 5.4%.
Biomerica (BMRA) shares surged 85% after the company said Thursday its Fortel prostate-specific antigen screening test has been approved by the United Arab Emirates Ministry of Health and Prevention for detection of prostate cancer.
Atara Biotherapeutics (ATRA) shares fell 38% after the company reported "compliance issues" involving a third-party manufacturing facility for Ebvallo, a treatment for people with Epstein-Barr virus positive post-transplant lymphoproliferative disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.